BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of “Hold” from Brokerages

BeiGene, Ltd. (NASDAQ:BGNEGet Rating) has been assigned an average recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $315.33.

Several equities analysts have commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of BeiGene in a research report on Thursday, January 13th. They set an “overweight” rating for the company. Zacks Investment Research lowered shares of BeiGene from a “hold” rating to a “sell” rating in a report on Wednesday, April 20th. StockNews.com initiated coverage on shares of BeiGene in a report on Thursday, March 31st. They set a “sell” rating for the company. Deutsche Bank Aktiengesellschaft initiated coverage on shares of BeiGene in a report on Monday, February 7th. They set a “buy” rating for the company. Finally, SVB Leerink lowered shares of BeiGene from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $300.00 to $177.00 in a report on Thursday, March 17th.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of BeiGene by 23.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,944 shares of the company’s stock valued at $3,950,000 after buying an additional 3,948 shares during the last quarter. Koshinski Asset Management Inc. grew its position in BeiGene by 139.6% during the 1st quarter. Koshinski Asset Management Inc. now owns 242 shares of the company’s stock worth $46,000 after purchasing an additional 141 shares during the period. IFM Investors Pty Ltd acquired a new stake in BeiGene during the 1st quarter worth about $326,000. E Fund Management Hong Kong Co. Ltd. grew its position in BeiGene by 137.7% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 27,501 shares of the company’s stock worth $5,071,000 after purchasing an additional 15,929 shares during the period. Finally, Norges Bank acquired a new stake in BeiGene during the 4th quarter worth about $93,834,000. 54.57% of the stock is currently owned by hedge funds and other institutional investors.

BGNE stock opened at $163.78 on Monday. BeiGene has a 52 week low of $136.09 and a 52 week high of $426.56. The company has a quick ratio of 4.61, a current ratio of 4.76 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $192.69 and a two-hundred day simple moving average of $262.77. The firm has a market capitalization of $16.81 billion, a P/E ratio of -10.80 and a beta of 0.76.

BeiGene (NASDAQ:BGNEGet Rating) last released its quarterly earnings data on Friday, February 25th. The company reported ($6.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($4.79) by ($1.37). BeiGene had a negative net margin of 120.15% and a negative return on equity of 32.85%. The business had revenue of $213.98 million for the quarter, compared to the consensus estimate of $220.70 million. As a group, analysts anticipate that BeiGene will post -15.66 EPS for the current year.

BeiGene Company Profile (Get Rating)

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Further Reading

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.